Premium
Anti‐MRSA Agent Discovery Using Diversity‐Oriented Synthesis
Author(s) -
Thomas Gemma L.,
Spandl Richard J.,
Glansdorp Freija G.,
Welch Martin,
Bender Andreas,
Cockfield Joshua,
Lindsay Jodi A.,
Bryant Clare,
Brown Derek F. J.,
Loiseleur Olivier,
Rudyk Hélène,
Ladlow Mark,
Spring David R.
Publication year - 2008
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.200705415
Subject(s) - natural product , staphylococcus aureus , class (philosophy) , computer science , diversity (politics) , phosphonate , drug discovery , methicillin resistant staphylococcus aureus , product (mathematics) , world wide web , computational biology , chemistry , biology , stereochemistry , bioinformatics , bacteria , sociology , mathematics , artificial intelligence , biochemistry , genetics , geometry , anthropology
Beating the superbugs : Diversity‐oriented synthesis using a solid‐supported phosphonate unit to synthesize 242 drug‐like compounds based on 18 natural‐product‐like scaffolds led to the discovery of gemmacin (see scheme). This new structural class of antibiotic is active towards methicillin‐resistant Staphylococcus aureus (MRSA).